Literature DB >> 26738673

Pulmonary Artery Denervation Attenuates Pulmonary Arterial Remodeling in Dogs With Pulmonary Arterial Hypertension Induced by Dehydrogenized Monocrotaline.

Ling Zhou1, Juan Zhang1, Xiao-Min Jiang2, Du-Jiang Xie1, Jin-Song Wang1, Li Li1, Bin Li2, Zhi-Mei Wang3, Alexander M K Rothman4, Allan Lawrie4, Shao-Liang Chen5.   

Abstract

OBJECTIVES: This study aimed to investigate sympathetic nerve (SN) ultrastructural changes and hemodynamic and pulmonary artery (PA) pathological improvements by pulmonary arterial denervation (PADN) in animals with pulmonary arterial hypertension (PAH), as well as the underlying mechanisms.
BACKGROUND: SN overactivity plays a role in PAH. Previous studies have reported short-term improvements in pulmonary arterial pressure (PAP) and cardiac function by PADN, but PA remodeling and the associated mechanisms remain unclear.
METHODS: Forty dogs were randomly (ratio of 1:3) assigned to the control (intra-atrial injection of N-dimethylacetamide, 3 mg/kg) and test (intra-atrial injection of dehydrogenized-monocrotaline, 3 mg/kg) groups. After 8 weeks, the animals in the test group with a mean PAP >25 mm Hg (n = 20) were randomized (ratio of 1:1) into the sham and PADN groups. At 14 weeks, the hemodynamics, medial wall thickness and PA muscularization, and messenger ribonucleic acid expression of genes in lung tissues were measured. Another 35 PAH dogs were used to measure the SN conduction velocity, electron microscopic assessment, and nerve distribution.
RESULTS: PADN induced significant SN demyelination and axon loss and slowed SN conduction velocity over time, with resulting profound reductions in the mean PAP (23.5 ± 2.3 mm Hg vs. 33.7 ± 5.8 mm Hg), pulmonary vessel resistance (3.5 ± 2.3 Wood units vs. 7.7 ± 1.7 Wood units), medial wall thickness (22.3 ± 3.3% vs. 30.4 ± 4.1%), and full muscularization (40.3 ± 9.3% vs. 57.1 ± 5.7%) and increased nonmuscularization (29.8 ± 6.1% vs. 12.9 ± 4.9%) compared with the Sham group (all p < 0.001). PADN inhibited the messenger ribonucleic acid expression of genes correlated with inflammation, proliferation, and vasoconstriction.
CONCLUSIONS: PADN induces permanent SN injury and subsequent improvements in hemodynamics and PA remodeling in animals with PAH through mechanisms that may be experimentally and clinically beneficial.
Copyright © 2015 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  electron microscopy; pathological remodeling; pulmonary arterial hypertension; pulmonary artery denervation; sympathetic nerves

Mesh:

Substances:

Year:  2015        PMID: 26738673     DOI: 10.1016/j.jcin.2015.09.015

Source DB:  PubMed          Journal:  JACC Cardiovasc Interv        ISSN: 1936-8798            Impact factor:   11.195


  16 in total

Review 1.  Emerging therapies for right ventricular dysfunction and failure.

Authors:  Anna Klinke; Torben Schubert; Marion Müller; Ekaterina Legchenko; Jason G E Zelt; Tsukasa Shimauchi; L Christian Napp; Alexander M K Rothman; Sébastien Bonnet; Duncan J Stewart; Georg Hansmann; Volker Rudolph
Journal:  Cardiovasc Diagn Ther       Date:  2020-10

Review 2.  Pulmonary Artery Denervation: Update on Clinical Studies.

Authors:  Hang Zhang; Shao-Liang Chen
Journal:  Curr Cardiol Rep       Date:  2019-09-05       Impact factor: 2.931

3.  Inhibition of CXCR4 ameliorates hypoxia-induced pulmonary arterial hypertension in rats.

Authors:  Jingjing Xu; Xiangnan Li; Siqi Zhou; Rui Wang; Mengxi Wu; Cheng Tan; Jingyu Chen; Zhiping Wang
Journal:  Am J Transl Res       Date:  2021-03-15       Impact factor: 4.060

4.  Beyond medications: is pulmonary artery denervation the answer for pulmonary arterial hypertension?: PADN for PAH.

Authors:  Fan Guo; Zhi-Cheng Jing
Journal:  AsiaIntervention       Date:  2022-03-15

5.  Perspectives of bilateral thoracic sympathectomy for treatment of heart failure.

Authors:  Raphael Dos Santos Coutinho E Silva; Fernando Luiz Zanoni; Rafael Simas; Luiz Felipe Pinho Moreira
Journal:  Clinics (Sao Paulo)       Date:  2021-08-04       Impact factor: 2.365

Review 6.  The progress of pulmonary artery denervation.

Authors:  Yonghui Xie; Na Liu; Zhenghui Xiao; Fang Yang; Yunhong Zeng; Zhou Yang; Yuanxi Xia; Zhi Chen; Yunbin Xiao
Journal:  Cardiol J       Date:  2021-01-13       Impact factor: 3.487

7.  Effects of renal denervation on monocrotaline induced pulmonary remodeling.

Authors:  Qian Liu; Jiyang Song; Dasheng Lu; Jie Geng; Zhixin Jiang; Kai Wang; Bin Zhang; Qijun Shan
Journal:  Oncotarget       Date:  2017-07-18

8.  Pulmonary artery denervation improves pulmonary arterial hypertension induced right ventricular dysfunction by modulating the local renin-angiotensin-aldosterone system.

Authors:  Chen Liu; Xiao-Min Jiang; Juan Zhang; Bing Li; Jing Li; Du-Jiang Xie; Zuo-Ying Hu
Journal:  BMC Cardiovasc Disord       Date:  2016-10-10       Impact factor: 2.298

9.  Transection of the cervical sympathetic trunk inhibits the progression of pulmonary arterial hypertension via ERK-1/2 Signalling.

Authors:  Yongpeng Zhao; Rui Xiang; Xin Peng; Qian Dong; Dan Li; Guiquan Yu; Lei Xiao; Shu Qin; Wei Huang
Journal:  Respir Res       Date:  2019-06-14

10.  Electrical Stimulation-Guided Approach to Pulmonary Artery Catheter Ablation in Patients with Idiopathic Pulmonary Arterial Hypertension: A Pilot Feasibility Study with a 12-Month Follow-Up.

Authors:  Natalia S Goncharova; Olga M Moiseeva; Heber Ivan Condori Leandro; Irina S Zlobina; Aelita V Berezina; Kirill N Malikov; Dmitry M Tashkhanov; Dmitry S Lebedev; Evgeny N Mikhaylov
Journal:  Biomed Res Int       Date:  2020-02-17       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.